MyMedicalRecords Files Patent Infringement Complaint Against Walgreens

MyMedicalRecords Files Patent Infringement Complaint Against Walgreens 
LOS ANGELES, CA -- (Marketwire) -- 01/31/13 --  MyMedicalRecords,
Inc. ("MMR"), a wholly owned subsidiary of MMRGlobal, Inc. (OTCQB:
MMRF), today announced the filing of a complaint for patent
infringement against Walgreen Co. The complaint alleges that
Walgreens is infringing on MMR's Personal Health Records patent,
specifically U.S. Patent No. 8,301,466, and as a result, MMR is
seeking monetary damages as well as a permanent injunction. As stated
in the complaint, Walgreens is the nation's largest drugstore chain
with fiscal 2012 sales of $72 billion, operating 8061 drugstores and
providing services to over 6 million customers. The complaint was
filed in the United States District Court for the Central District of
California, case number CV 13-00631, on January 29 and is available
on the court's website  
MMR is a leading provider of Personal Health Records (PHRs),
MyEsafeDepositBox storage solutions, and MMRPro document management
and imaging systems for healthcare professionals. MMR currently has
seven U.S. Health IT patents: U.S. Patent Nos. 8,301,466; 8,352,287;
8,352,288; 8,121,855; 8,117,646; 8,117,045; and 8,321,240. The MMR
Patent Portfolio includes nearly 400 claims as well as additional
applications and continuation applications. The patents involve
inventions pertaining to Personal Health Records, Patient Portals and
other Electronic Health Record systems. MMR also has been granted
patents and has other pending applications in countries of commercial
interest including Australia, Singapore, New Zealand, Mexico, Japan,
Canada, Hong Kong, South Korea, Israel, and European nations. 
Working with Liner Grode Stein Yankelevitz Sunshine Regenstreif &
Taylor LLP, MMR is pursuing efforts to monetize its patent portfolio
and other IP by investigating potential infringement of MMR's patents
by entities such as retail pharmacies, EHR and PHR vendors,
laboratory systems, hospitals, physicians, and other healthcare
On January 23, 2013, published an article regarding
the MMR Patents linking to a Research and Valuation report. The
report discusses how more than 5500 hospitals, 150 PHR vendors and 
750 EMR vendors as well as providers, payers and pharmacies are
potential licensees of the MMR Patent Portfolio. The Valuation covers
MMR's U.S. Patents and does not include its issued patents and
pending applications in twelve additional countries. Since the
publication of the report less than two weeks ago, MMR received
notice of Health IT patent approvals in Japan. To go directly to the
report, visit 
For additional information regarding the MyMedicalRecord, Inc.
complaint against Walgreen Co., contact Ted Ward at Liner Grode Stein
Yankelevitz Sunshine Regenstreif & Taylor LLP at (310) 500-3384. 
About MMRGlobal
 MMRGlobal, Inc., through its wholly-owned operating
subsidiary, MyMedicalRecords, Inc., provides secure and easy-to-use
online Personal Health Records ("PHRs") and electronic safe deposit
box storage solutions, serving consumers, healthcare professionals,
employers, insurance companies, financial institutions, retail
pharmacies, and professional organizations and affinity groups. The
MyMedicalRecords PHR enables individuals and families to access their
medical records and other important documents, such as birth
certificates, passports, insurance policies and wills, anytime from
anywhere using the Internet. MyMedicalRecords is built on
proprietary, patented technologies to allow documents, images and
voicemail messages to be transmitted and stored in the system using a
variety of methods, including fax, phone, or file upload without
relying on any specific electronic medical record platform to
populate a user's account. The Company's professional offering,
MMRPro, is designed to give physicians' offices an easy and
cost-effective solution to digitizing paper-based medical records and
sharing them with patients through an integrated patient portal.
Through its merger with Favrille, Inc. in January 2009, the Company
acquired intellectual property biotech assets that include anti-CD20
antibodies and data and samples from its FavId(TM)/Specifid(TM)
vaccine clinical trials for the treatment of B-Cell Non-Hodgkin's
lymphoma. To learn more about MMRGlobal, Inc. visit View demos and video tutorials of the Company's
products and services at 
Forward-Looking Statements 
 All statements in this press release
that are not strictly historical in nature, including, without
limitation, intellectual property enforcement actions, infringement
claims or litigation, intellectual property licenses, and future
performance, management's expectations, beliefs, intentions,
estimates or projections, constitute "forward-looking statements."
Such forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the Company's actual
results to be materially different from historical results or from
any results expressed or implied by such forward-looking statements.
Some can be identified by the use of words (and their derivations)
such as "need," "possibility," "potential," "intend," "offer,"
"development," "if," "negotiate," "when," "begun," "believe,"
"achieve," "will," "estimate," "expect," "maintain," "plan," and
"continue," or the negative of these words. Actual outcomes and
results of operations and the timing of selected events may differ
materially from the results predicted, and any reported results
should not be considered as an indication of future performance. Such
statements are necessarily based on assumptions and estimates and are
subject to various risks and uncertainties, including those relating
to the possible invalidity of the underlying assumptions and
estimates and possible changes or developments in economic, business,
industry, market, legal and regulatory circumstances and conditions
and actions taken or omitted to be taken by third parties, including
customers, suppliers, business partners, potential licensees,
competitors and legislative, judicial and other governmental
authorities and officials. Factors that could cause or contribute to
such differences include, but are not limited to: unexpected outcomes
with respect to intellectual property enforcement actions, claims of
intellectual property infringement and general intellectual property
litigation; our ability to maintain, develop, monetize and protect
our patent portfolio for both the Company's health IT and
biotechnology intellectual property assets in the U.S. and
internationally; research and valuation reports on the Company; the
timing of milestone payments in connection with licensing our
intellectual property; our ability to establish and maintain
strategic relationships; changes in our relationships with our
licensees; the risk the Company's products are not adopted or viewed
favorably by the healthcare community and consumer retail market;
business prospects, results of operations or financial condition;
risks related to the current uncertainty and instability in financial
and lending markets, including global economic uncertainties; the
timing and volume of sales and installations; the length of sales
cycles and the installation process; the market's acceptance of new
product and service introductions; competitive product offerings and
promotions; changes in government laws and r
egulations including the
2009 HITECH Act and changes in Meaningful Use and the 2010 Affordable
Care Act; future changes in tax legislation and initiatives in the
healthcare industry; undetected errors in our products; the
possibility of interruption at our data centers; risks related to
third party vendors; risks related to obtaining and integrating
third-party licensed technology; risks related to a security breach
by third parties; risks associated with recruitment and retention of
key personnel; other litigation matters; uncertainties associated
with doing business internationally across borders and territories;
and additional risks discussed in the Company's filings with the
Securities and Exchange Commission including disclosures about the
Company's relationship with the Michael Bass Group since 2009. The
Company is providing this information as of the date of this release
and, except as required by applicable law, does not undertake any
obligation to update any forward-looking statements contained in this
release as a result of new information, future events or otherwise.  
Michael Selsman
Public Communications Co.
(310) 922-7033 
Press spacebar to pause and continue. Press esc to stop.